Liaising. CTI shall keep TGTX promptly and regularly informed of the course of the filing and prosecution of DFCI Patents or related proceedings (e.g. interferences, oppositions, reexaminations, reissues, revocations or nullifications) in a timely manner, and to reasonably take into consideration the advice and recommendations of TGTX.
Appears in 3 contracts
Samples: Collaboration Agreement (Checkpoint Therapeutics, Inc.), Collaboration Agreement (Checkpoint Therapeutics, Inc.), Collaboration Agreement (Tg Therapeutics, Inc.)
Liaising. CTI shall keep TGTX promptly and regularly informed of the course of the filing and prosecution of DFCI Patents and patents included in Additional PD-L1 Intellectual Property for which CTI is responsible or related proceedings (e.g. e.g., interferences, oppositions, reexaminations, reissues, revocations or nullifications) in a timely manner, and to reasonably take into consideration the advice and recommendations of TGTX.
Appears in 2 contracts
Samples: Collaboration Agreement (Checkpoint Therapeutics, Inc.), Collaboration Agreement (Tg Therapeutics, Inc.)
